List of Diagnostics Companies in New Jersey - 22

Accu Reference Medical Lab is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government’s Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology. As new medical tests become available, we update our list of services. Our laboratory technicians are well trained and have many years of experience, providing the most accurate and precise testing results. We also continuously strive to improve the quality of our testing, data handling and reporting through integrating robust technique and technological advancements. Accu Reference Medical Lab is an equal opportunity employer.

Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider. The Company engages in the management of stem cell banks and specialty clinical laboratories. It is developing of exosome technology to improve the diagnosis and management of diseases. The Company operates through two platforms, Avalon Cell and Avalon Rehab. Its technology and service ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company also focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable.

DiamiR developsand diagnostictechnology based on analysis of brain-enriched microRNA biomarkers in blood plasma.

DRG International, Inc. is a leading specialty medical diagnostics and equipment manufacturer, and distributor with operations in more than 110 countries. As a global innovator of high-quality medical diagnostics and equipment, DRG International, Inc.'s mission is to provide the medical and research community with cutting edge, effective tools to build a healthier future. DRG® offers various laboratory immunodiagnostic products and equipment. In addition, DRG®, in cooperation with major U.S. and foreign suppliers, is a leading distributor for cardiac, electrophysiology, and angiology equipment and supplies in certain markets. DRG® provides a complete range of services including delivery, customs clearance, installation, on-site training and technical support as well as after-warranty service.

EDDA Technology, Inc. is an innovative leader in the rapidly growing field of imaging-guided cancer treatment. By adopting a fully quantitative, real-time interactive approach to imaging analysis, simulation and guidance, our next generation computer-assisted radiology and surgery solutions go well beyond advanced 3D image visualization. The award-winning IQQA® platform supports a patient-specific, disease-targeted, and multi-disciplinary approach to cancer treatment. With exceptional ease-of-use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up. The IQQA® platform provides targeted solutions to assist physicians in advanced clinical applications including: fast 3D quantitative analysis and visualization, highly automated volumetric organ/lesion segmentation & quantification, pre– & post–operative assessment, treatment planning & simulation, procedural guidance and monitoring, and Computer-Aided Detection (CAD).

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Ethos Biosciences designs, develops, and manufactures diagnostics that are accurate, repeatable, and easy to use. Ethos Biosciences was formed as a subsidiary of Ott Scientific in 2018 to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. In November 2018, Ethos Biosciences acquired the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals. Exocell was founded in 1988 by Dr. Margo Cohen, MD/PhD to explore diagnostic and therapeutic solutions for diabetes. Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. The Exocell brand continues to service the top research, academic, and industrial institutions in the world. Ott Scientific is a family owned and operated group of specialty chemical manufacturing companies with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.

At Glucotrack, we are pioneers in diabetes technology, dedicated to transforming the way diabetes is managed. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. With a commitment to reducing the daily burden of diabetes management, we create cutting-edge technologies designed to enhance the lives of those we serve. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering.

Ingenio Diagnostics (ID), a Genesis Drug Discovery and Development (GD3) Member Company, combines experience in Pharmaceutical, Biotechnology, and CRO services with a clinical diagnostic laboratory's licensure and accreditation. We deliver clinical diagnostic laboratory services and specialty testing with the additional benefit of dedicated quality assurance & quality control division. Our highly-skilled team of scientists, clinical, and operations personnel have extensive experience analyzing a wide variety of patient specimen types, spanning multiple analytical platforms in many therapeutic areas.

Interpace Biosciences develops molecular diagnostic tests under the brand Interpace Diagnostics, and provides clincal trial services under the brand Interpace PharaSolutions.

Koios DS™ is a Smart Ultrasound™ solution for radiologists diagnosing cancer. Using AI algorithms trained on tens of thousands of images combined with data from pathology results, Koios DS™ is clinical decision support for a new era of diagnostic excellence. Smart Ultrasound™ redefines what radiology professionals can discern in the radiology suite. Our proprietary technology and patented methods provide an invaluable “second opinion” that is already being adopted by leading healthcare institutions to improve diagnostic accuracy, speed clinical decision making, and elevate the quality of care. Our software is FDA cleared for use in the USA. Koios DS. We put the AI in ultrasound.

Medical Diagnostic Laboratories, L.L.C. (MDL), founded in 1997, serves primarily as a reference laboratory for Polymerase Chain Reaction (PCR) based testing to physicians, laboratories and hospitals worldwide. MDL is a CLIA certified infectious disease laboratory with multiple state licenses specializing in PCR technology. Molecular diagnostic techniques, such as the PCR method, are considered to be the most sensitive and specific for the laboratory diagnosis of infectious diseases. MDL offers unique, non-invasive, highly stable specimen collection and transport platforms, such as the OneSwab®, UroSwab® and NasoSwab®. These platforms enable MDL to offer a variety of PCR based tests from a single swab with high sensitivity and specificity. MDL specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties valuable tailored diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections. For example, the unique testing MDL offers for the specialties of Urology and Gynecology enables the detection of multiple pathogens as well as certain drug resistance profiles from a single swab by PCR. MDL's primary focus is in the field of infectious disease testing for Urology, Obstetrics and Gynecology, Respiratory Infectious diseases, Vector-borne diseases, Mycology and Pharmacogenomics. MDL is comprised of experts in the fields of Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance and Oncology. In addition to developing and validating new clinical diagnostic tests, the Research and Development Department also publishes research projects in peer-reviewed journals, presents scientific information at international symposia, and performs contractual research work for major commercial, governmental, and academic organizations.

Menssana Research is the leading developer of advanced new breath tests for detection of disease. We are now performing clinical studies with the BCA and with BreathLink (TM), mostly funded by the National Institutes of Health and BARDA, to evaluate breath testing in several diseases including lung cancer, breast cancer, heart transplant rejection, radiation exposure, and tuberculosis. The Food and Drug Administration has approved the Heartsbreath test for heart transplant rejection for clinical use. For more information, please visit menssanaresearch.com.

Mestastop Solutions is a biotechnology startup based in India, focused on addressing cancer metastasis. The company aims to develop innovative solutions to combat the spread of tumors, which significantly contributes to cancer-related deaths worldwide. Mestastop has gained global recognition for its research, presenting its work at major international conferences such as the American Association of Cancer Research Annual Conference and the European Association of Cancer Research. The company is involved in diagnostics and discovery related to cancer metastasis, with a focus on small molecule drugs to tackle distant metastasis. Mestastop's approach includes unraveling the biology of metastasis to create targeted treatments. The company has been vetted by the scientific outsourcing platform Science Exchange and is recognized as an authorized service provider, underscoring its credibility in the field.

Electrodiagnostics

Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testingVitros Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators - EUA 4/2020

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

Princeton BioMeditech Corporation develops rapid, point-of-care diagnostics. Utilizing its patented technologies, PBM has developed and introduced an extensive menu of over 70 different one-step/rapid tests.COVID-19: EUA (02/2021)

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

In 2017, IEH Laboratories and Consulting Group acquired the Atlas technology from Roka Bioscience. The IEH Laboratories and Consulting Group family of companies continues to grow. IEH now employs more than 1,800 employees in eight countries (Australia, Austria, Canada, China, England, Germany, Mexico, and the USA). We also recently completed the acquisitions of: Sample6, Unitech, Toximet, Biomerx Laboratorium GmbH, VIL Institut fur Lebensmittelsicherheit, Labor Iben GmbH, and Iben Mikro Stop GmbH. In addition, we have expanded our expertise by welcoming new experts to the IEH family for consulting services including former FDA, USDA and industry senior leaders to further assist the food industry. The Roka and Sample6 acquisitions have allowed us to expand our capabilities in rapid pathogen detection and automation. We have now validated both systems for the detection of Listeria in food samples after only 10-15 hours of enrichment, and same day results are available for environmental samples

SCIMEDX is a diagnostic manufacturer with over 30 years of proven experience. Best known for its range of autoimmune and infectious disease testing products. Scimedx extends it's platforms for disease testing. The first was ImmuoCyt+ an FDA cleared & patented assay for bladder cancer. From there Scimedx expanded it's IFA and Latex Infectious assays by acquiring PANBIO for HHV, Dengue, West Nile. Scimedx then went on to acquire Parasitology serology assays from IVD Research. Continuing it's growth, Scimedx has finalized it's rapid testing platform. Scimedx is the de-facto manufacturer of IFA, ELISA, Agglutination tests, delivering solutions for disease testing worldwide.

SpotitEarly is revolutionizing cancer pre-screening with an innovative AI-based test that can detect multiple cancer types from a single breath sample. This simple solution allows for easy, at-home sample collection in minutes, without any healthcare professional assistance. Our off-the-shelf test is affordable and available everywhere, at everyone’s convenience, removing the barriers that keep about half of the people from getting tested on time. With an impressive 94% accuracy (sensitivity and specificity), our technology has been shown to be effective even in early-stage cancer detection, which can significantly increase treatment options and survival rates. By harnessing the science of scent, SpotitEarly identifies cancerous VOCs in exhaled breath. This smart technology enables more frequent testing of wider audiences at a fraction of the cost, ultimately saving lives and improving clinical outcomes globally. We envision a world where hassle-free pre-screening is the norm. Join us in our mission to make cancer prevention easy, effective, and universally accessible, bringing enhanced quality of life and peace of mind for all.